195
Participants
Start Date
August 30, 2023
Primary Completion Date
January 15, 2025
Study Completion Date
January 15, 2025
TQH3821 tablets 200 mg
TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
TQH3821 tablets matching placebo
TQH3821 tablets matching placebo without active substance.
Peking University Shougang Hospital, Beijing
The Peking University People's Hospital, Beijing
Central Hospital of Jinzhou, Jinzhou
Jilin Provincial People's Hospital, Changchun
China-japan Friendship Hospital of Jilin University, Changchun
The First Affiliated Hospital of Harbin Medical University, Harbin
The First Hospital of Qiqihar, Qiqihar
Tongji Hospital, Shanghai
Nanjing Drum Tower Hospital, Nanjing
The First Affiliated Hospital of Soochow University, Suzhou
Bozhou People's Hospital, Bozhou
Yantaishan Hospital of Yantai, Yantai
Heze Municipal Hospital, Heze
Zaozhuang Municipal Hospital, Zaozhuang
Second Hospital of Tianjin Medical University, Tianjin
Yuyao People's Hospital, Yuyao
Wenling First People's Hospital, Taizhou
Taizhou Central Hospital Taizhou University Hospitai, Taizhou
Pingxiang People's Hospital, Pingxiang
The Southwest Hospital of AMU, Chongqing
Xiangya Third Hospital of Central South University, Changsha
Shiyan Renmin Hospital, Shiyan
People's Hospital of Zhengzhou, Zhengzhou
Anyang District Hospital of Puyang City, Anyang
Puyang Oilfield General Hospital, Puyang
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou
Guangxi Zhuang Autonomous Region People's Hospital, Nanning
Chengdu Fifth People's Hospital, Chengdu
First Affiliated Hospital of Kunming Medical University, Kunming
The First Affiliated Hospital of PLA Air Force Medical University, Xi’an
Hebei Provincial People's Hospital, Shijiazhuang
Heping Hospital Affiliated to Changzhi Medical College, Changzhi
First Hospital of Shanxi Medical University, Taiyuan
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY